Cost-Effectiveness of Crizotinib for Second and Third-Line Treatment of Non-Small Cell Lung Cancer in Ecuador

May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.194
https://www.valueinhealthjournal.com/article/S1098-3015(18)30494-7/fulltext
Section Title :
Section Order : 1046
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30494-7&doi=10.1016/j.jval.2018.04.194
HEOR Topics :
Tags :
Regions :